EPOK Therapeutics
About
EPOK Therapeutics was launched in February 2023 to discover and develop biologics to treat metabolic diseases. It is built on over two decades of experience and innovation in antibody engineering and preclinical studies of metabolic diseases in the founders’ labs. Co-founders Professor Sachdev Sidhu, Ph.D., and Professor Orson Moe, MD, have proven track records as investors, entrepreneurs, and contributors to the discovery, development, and launch of successful drugs.
EPOK Therapeutics develops engineered agonist and antagonist antibodies and antibody conjugates. Its unique approach minimizes off-target actions, a better safety profile, a significantly reduced dosing frequency, and lower manufacturing costs. EPOK Therapeutics’ current focus areas are anemia and phosphate disorders associated with several genetic and acquired disease conditions, including CKD.
EPOK Therapeutics Inc. is incorporated in the Province of Ontario, Canada, with a principal place of business at 333 Bay Street, Suite 2400, Toronto, ON, Canada M5H 2T6 and with a subsidiary EPOK Therapeutics USA Inc., registered as a Delaware corporation with operations at 31363 Medallion Drive, Hayward, CA 94544.